Fluoxetine Hydrochloride Treatment Influences Site-Specific ADAR Editing and Transcriptome Regulation in Arid1b +/- Mice
- 1Kent State University
Abstract
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behavior and impaired social interactions. Recent reports from human postmortem brain samples of ASD show transcriptome-wide dysregulations, including changes in differential gene expression and alternative splicing. An important mechanism regulating transcriptome function is the editing of double-stranded RNA by adenosine deaminases acting on RNA (ADARs), which play regulatory roles in neurodevelopment and innate immunity. We explore the ADAR editing changes associated with the use of Selective Serotonin Reuptake Inhibitors (SSRIs) in Arid1b haploinsufficient mouse models. Our results show dynamic changes in site-specific editing rates in autistic mice. We further demonstrate the transcriptome-wide effects of differential ADAR editing in terms of changes in miRNA-mRNA interactions. Moreover, our findings highlight a site-specific change in editing rates for evolutionarily conserved sites in mammals and ASD associated risk genes, such as Gria2. Our analysis of significant biological processes shows the association of differentially edited genes with processes vital for neurotransmission. Overall, our findings imply that the use of SSRIs can induce distinct ADAR editing signatures, potentially contributing to ASD pathology.
Related
- A Re‐Appraisal of Three Network Meta‐Analyses to Explain the Discrepancy in Findings for the Efficacy of Fluoxetine for the Treatment of Depression in Children and Adolescents
- Fetal sex influences molecular regulation of human placental vascular development across gestation
- Indirect Influences of Artificial Intelligence Advice on Complex Sepsis Treatment Decisions
- Single-cell transcriptome profiling of post-treatment and treatment-naïve colorectal cancer: Insights into putative mechanisms of chemoresistance
- Lacticaseibacillus rhamnosus GG enhances gefitinib efficacy and reduces treatment-related toxicity via propionyl-L-carnitine regulation
BibTeX
@misc{tariq2026fluoxetine,
title = {{Fluoxetine Hydrochloride Treatment Influences Site-Specific ADAR Editing and Transcriptome Regulation in Arid1b +/- Mice}},
author = {A. Tariq and H. Piontkivska},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.24.753309},
url = {https://www.biorxiv.org/content/10.64898/2026.09.24.753309v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Fluoxetine Hydrochloride Treatment Influences Site-Specific ADAR Editing and Transcriptome Regulation in Arid1b +/- Mice
AU - A. Tariq
AU - H. Piontkivska
PY - 2026
DA - 2026/09/24
PB - bioRxiv
DO - 10.64898/2026.09.24.753309
UR - https://www.biorxiv.org/content/10.64898/2026.09.24.753309v1
AB - Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behavior and impaired social interactions. Recent reports from human postmortem brain samples of ASD show transcriptome-wide dysregulations, including changes in differential gene expression and alternative splicing. An important mechanism regulating transcriptome function is the editing of double-stranded RNA by adenosine deaminases acting on RNA (ADARs), which play regulatory roles in neurodevelopment and innate immunity. We explore the ADAR editing changes associated with the use of Selective Serotonin Reuptake Inhibitors (SSRIs) in Arid1b haploinsufficient mouse models. Our results show dynamic changes in site-specific editing rates in autistic mice. We further demonstrate the transcriptome-wide effects of differential ADAR editing in terms of changes in miRNA-mRNA interactions. Moreover, our findings highlight a site-specific change in editing rates for evolutionarily conserved sites in mammals and ASD associated risk genes, such as Gria2. Our analysis of significant biological processes shows the association of differentially edited genes with processes vital for neurotransmission. Overall, our findings imply that the use of SSRIs can induce distinct ADAR editing signatures, potentially contributing to ASD pathology.
ER -